Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
biomarker
chemotherapy
eribulin
neutrophil to lymphocyte ratio
pazopanib
peripheral immune-related marker
platelet to lymphocyte ratio
prognosis
soft tissue sarcoma
trabectedin
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
26 Oct 2021
26 Oct 2021
Historique:
received:
04
10
2021
revised:
23
10
2021
accepted:
25
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
Pazopanib, trabectedin, and eribulin are administered for the treatment of soft tissue sarcomas (STSs); however, there is little consensus on which agent should be preferentially used in a clinical setting. This study assessed whether peripheral immune-related markers served as a useful reference when selecting pazopanib, trabectedin, or eribulin. This study included 63 patients who were administered pazopanib, trabectedin, or eribulin for advanced STSs between March 2015 and December 2020. Patients were divided into three groups based on the first drug administered among these three drugs. Differences in overall survival (OS) or progression-free survival (PFS) among the three groups were analyzed. OS showed no significant differences among the drugs administered first. For patients with low neutrophil-to-lymphocyte ratio (NLR), the OS of patients administered pazopanib as the first choice was shorter than the others (hazard ratio [HR] = 9.53, 95% confidence interval [CI] = 1.94-18.13,
Identifiants
pubmed: 34768491
pii: jcm10214972
doi: 10.3390/jcm10214972
pmc: PMC8584915
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 18K16627
Organisme : Japan Society for the Promotion of Science
ID : 19K16802
Organisme : Japan Society for the Promotion of Science
ID : 21K09325
Références
Cancer Sci. 2017 Nov;108(11):2273-2280
pubmed: 28869796
Sci Rep. 2020 Dec 1;10(1):20896
pubmed: 33262403
Ann Gastroenterol Surg. 2020 Jul 08;4(5):580-590
pubmed: 33005853
Mol Cancer. 2017 Aug 15;16(1):137
pubmed: 28810877
Bratisl Lek Listy. 2001;102(1):5-14
pubmed: 11723675
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
Lancet Oncol. 2015 Apr;16(4):406-16
pubmed: 25795406
Lancet. 2008 Mar 1;371(9614):771-83
pubmed: 18275997
Clin Colorectal Cancer. 2018 Dec;17(4):e741-e749
pubmed: 30219280
Lancet. 2016 Apr 16;387(10028):1629-37
pubmed: 26874885
Front Oncol. 2019 Sep 24;9:955
pubmed: 31608240
Int J Clin Oncol. 2018 Aug;23(4):634-640
pubmed: 29442281
J Surg Oncol. 2005 Sep 1;91(3):181-4
pubmed: 16118772
Curr Oncol. 2020 Feb;27(Suppl 1):25-33
pubmed: 32174755
J Gynecol Oncol. 2012 Oct;23(4):265-73
pubmed: 23094130
J Cancer. 2018 May 25;9(12):2132-2139
pubmed: 29937932
Anticancer Res. 2021 Jan;41(1):527-532
pubmed: 33419852
Cells. 2020 Apr 01;9(4):
pubmed: 32244723
Cancer Med. 2016 Oct;5(10):2792-2799
pubmed: 27683208
Mar Drugs. 2014 Jan 27;12(2):719-33
pubmed: 24473171
Breast Cancer. 2020 Jul;27(4):706-715
pubmed: 32133606
J Orthop Surg (Hong Kong). 2019 May-Aug;27(2):2309499019854957
pubmed: 31221016
Lancet Oncol. 2017 Oct;18(10):1397-1410
pubmed: 28882536
J Clin Lab Anal. 2019 Oct;33(8):e22964
pubmed: 31282096
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336